Evidence map›Paper›PMID 32995719›Full record

ArticleCJC open2020

Canadian Real-World Experience of Using Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction: Insight From the PARASAIL Study.

Haissam Haddad, Sebastien Bergeron, Andrew Ignaszewski, Gregory Searles, Driss Rochdi, Priyanka Dhage, Natacha Bastien

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CJC open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Cost-effectiveness and system-wide impact of using Hepatitis C-viremic donors for heart transplant.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2022
    Article
  12. Article
  13. Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Haissam HaddadDepartment of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Sebastien BergeronDepartment of Medicine, Centre de Recherche de l'Institut, Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Québec, Canada.
Andrew IgnaszewskiDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Gregory SearlesDepartment of Medicine, Saint John Regional Hospital, Saint John, New Brunswick, Canada.
Driss RochdiMedical Affairs, Novartis Pharmaceuticals Canada Inc., Dorval, Québec, Canada.
Priyanka DhageBiostatistics and Statistical Programming, Novartis Pharmaceuticals Pvt. Ltd., Hyderabad, India.
Natacha BastienMedical Affairs, Novartis Pharmaceuticals Canada Inc., Dorval, Québec, Canada.
Novartis (Canada) · CAInstitut universitaire de cardiologie et de pneumologie de Québec · CANovartis (India) · INSaint John Regional Hospital · CAUniversity of British Columbia · CAUniversity of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo determine the effectiveness of sacubitril/valsartan 97/103 mg twice daily (b.i.d.) on tolerability, safety, and quality of life (QoL) in Canadian patients with heart failure with reduced ejection fraction in a real-life setting.

methodsIn

resultsFor the 302 patients included, the mean age was 64.47 years, and a majority of patients (82.8%) belonged to New York Heart Association class II. Overall, 195 (64.6%) patients were on maximum dose of sacubitril/valsartan 97/103 mg b.i.d. after 6 months and 62.3% remained on this dose at month 12. Using patient global assessment, patients experienced an improvement in QoL. For Minnesota Living with Heart Failure Questionnaire scores, a significant decrease from the baseline was observed at weeks 4, 12, and 24 (

conclusionsResults of the PARASAIL study in a real-life setting have shown that most patients were on sacubitril/valsartan 97/103 mg b.i.d. and the treatment was well tolerated. The patient-reported outcomes showed an overall improvement in patients' QoL.

Identifiers

PMID32995719
PMCPMC7499388
OpenAlexW3022306844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.